ClinicalTrials.gg
Active, not recruitingNCT04734665NIRVANA-RUpdated Nov 18, 2026

Niraparib and Bevacizumab Maintenance Therapy in Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor

A Phase 2 interventional study of Niraparib-Bevacizumab in Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor, sponsored by Yonsei University. Active, not recruiting at 7 sites in South Korea. Open to female participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Yonsei University · Phase 2, Interventional, and Treatment

How we know · 2 judgments

Updated Nov 18, 2026Now Active, not recruitingPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
44
Allocation
Not applicable
Ages
20 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Ovarian Neoplasms by Yonsei University — 4 open to participants now, 6 under way, none of them phase 3. Ovarian Neoplasms · Yonsei University.

Started
2021
the only one that year
Phase 2
7 of 14
1 open now
Registered
7th of 14
by date

Among the 14 studies in Ovarian Neoplasms by Yonsei University, this one is the only one that started in 2021, is one of 7 in phase 2, and was the 7th registered.

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

4 of the 14 studies in Ovarian Neoplasms by Yonsei University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 603 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.

This study: 20 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Ovarian Neoplasms by Yonsei University, or all of them as a file.
02

Study summary

This study is phase II, open label, clinical trial to determine the efficacy of Niraparib re-treatment with Bevacizumab of assessment progression-free survival(6 months PFS rate) with platinum-sensitive recurrent ovarian cancer patients previously treated with a PARP inhibitor.

Read the detailed description

This is a Phase II, open-label, non-randomized, multi-center study assessing the efficacy and safety of Niraparib re-treatment with Bevacizumab of assessment progression-free survival(6 months PFS rate) with platinum-sensitive recurrent ovarian cancer patients previously treated with a PARP inhibitor The study will assess the effectiveness of progression-free survival(6 months PFS rate) as determined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. The subject will be treated to until disease progression as below:

  • Niraparib 200mg or 300mg (once daily[QD])*
  • Bevacizumab 15mg/kg every 3 weeks (Q3W)

    • The recommended starting dosage of niraparib is 200mg QD. For patients who weigh ≥77 kg and have baseline platelet count ≥150,000/μL, the recommended starting dosage is 300 mg QD.
03

Conditions studied

  • Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor

Browse trials for

Keywords

  • ovarian cancer, Platinum-sensitive, PARP inhibitor
04

Who can participate

The criteria were revised on the registry on Nov 18, 2026. See what changed

Ages eligible
20 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

## Inclusion Criteria

Participants are eligible to be included in the study only if all of the following criteria apply:

  1. Participant has a confirmed diagnosis of high-grade predominantly serous, endometrioid, carcinosarcoma, mixed Müllerian carcinoma with a high-grade serous component, clear cell, or low-grade serous ovarian cancer, primary peritoneal cancer, or fallopian tube cancer. Only up to 4 participants with clear cell carcinoma will be included. Mucinous carcinoma will not be included.
  2. Participant has received at least 2 previous courses of platinum-containing therapy and has disease considered platinum-sensitive following the penultimate (next-to-last) platinum regimen, defined as more than 12 months between the penultimate platinum regimen and disease progression.

    Note: The last platinum regimen does not necessarily have to immediately follow the penultimate platinum regimen. Participants who received a non-platinum regimen between the penultimate and last platinum regimens may be eligible if all other entry criteria are met.

  3. Participant has achieved a complete response (CR) or partial response (PR) to the last platinum regimen, remains in response, and is enrolled within 8 weeks after completion of the last platinum regimen.
  4. Participant has received prior treatment with a PARP inhibitor.
  5. Participant is able to provide a newly obtained core or excisional of a tumor lesion for prospective testing of BRCA1/2 and status prior to enrollment.
  6. Female participant aged ≥20 years on the day of signing .
  7. Participant has an (ECOG) performance status of 0 or 1, assessed within 10 days prior to enrollment.
  8. Participant is not pregnant or breastfeeding and meets at least one of the following conditions:

    • Is not a woman of (WOCBP), as defined in Appendix 2; OR
    • Is a WOCBP who agrees to follow the guidance in Appendix 2 during treatment and for at least 180 days after the last dose of niraparib and at least 180 days after the last dose of chemotherapy or bevacizumab.
  9. Participant or a legally acceptable representative provides written informed consent. Consent for future biomedical research is optional and is not required for participation in the main study.
  10. Participant has adequate organ function according to the following laboratory criteria. All screening laboratory tests must be performed within 10 days prior to the start of study treatment.

**Hematological Function:**

  • (ANC) ≥1,500/µL.
  • count ≥100,000/µL.
  • ≥9.0 g/dL or ≥5.6 mmol/L, without erythropoietin dependency. **Renal Function:**
  • Serum creatinine ≤1.5 × (ULN); OR
  • Measured or calculated (CrCl) ≥30 mL/min for participants with serum creatinine >1.5 × institutional ULN. (GFR) may be used instead of creatinine or CrCl. CrCl should be calculated according to institutional standards.

**Hepatic Function:**

  • Total ≤1.5 × ULN; OR direct bilirubin ≤ULN for participants with total bilirubin >1.5 × ULN.
  • (AST) and alanine aminotransferase (ALT) ≤2.5 × ULN (≤5 × ULN for participants with liver ).

**Coagulation Function:**

  • (INR) or prothrombin time (PT), and activated partial thromboplastin time (aPTT) ≤1.5 × ULN, unless the participant is receiving anticoagulant therapy, provided that PT or aPTT is within the therapeutic range for the intended anticoagulant use.

Note: Laboratory requirements should be adapted according to applicable local regulations and guidelines for the administration of specific chemotherapies.

## Exclusion Criteria

Participants are excluded from the study if any of the following criteria apply:

  1. Participant has mucinous, germ cell, or borderline tumor of the ovary.
  2. Participant has a history of non-infectious pneumonitis requiring treatment or currently has pneumonitis.
  3. Participant has myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), or features suggestive of MDS/AML.
  4. Participant has an additional that is progressing or has required active treatment within the past 2 years.

    Exceptions:

    • Basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g., breast carcinoma, cervical carcinoma in situ, or endometrial carcinoma) that has undergone potentially curative therapy.
    • Synchronous primary endometrial cancer or a history of primary endometrial cancer not exceeding Stage IA, with no more than superficial myometrial invasion.
  5. Participant has undergone drainage of ascites during the last 2 cycles of the most recent chemotherapy.
  6. Participant has received palliative radiotherapy encompassing >20% of the bone marrow within 1 week.
  7. Participant has persistent toxicity greater than Grade 2 from prior cancer therapy.
  8. Participant has symptomatic uncontrolled brain or . A scan confirming the absence of is not required. Participants with spinal cord compression may be eligible if they have received definitive treatment and have had clinically stable disease for 28 days.
  9. Participant has known to the components of niraparib or bevacizumab.
  10. Participant has undergone major surgery within 3 weeks prior to starting study treatment or has not recovered from the effects of major surgery.
  11. Participant is considered a poor medical risk due to a serious uncontrolled medical disorder, non-malignant systemic disease, or active uncontrolled infection, including but not limited to:

    • Uncontrolled ventricular arrhythmia, myocardial infarction within the past 3 months, or congestive cardiac failure.
    • Uncontrolled hypertension, defined as systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg, documented by 2 readings at least 1 hour apart.
    • Arterial or venous thromboembolism.
    • Uncontrolled cerebrovascular disease or predisposition to bleeding.
    • intestinal obstruction, abdominal fistula, or gastrointestinal perforation.
    • Uncontrolled major seizure disorder.
    • Unstable spinal cord compression.
    • Superior vena cava syndrome.
    • Any psychiatric disorder that prevents obtaining informed consent.
  12. Participant has a history or current evidence of any condition, therapy, or laboratory abnormality that may confound study results, interfere with participation throughout study treatment, or make participation not in the participant's best interest.
  13. Participant is .
  14. Participant has known active hepatic disease, including or C.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
44 participants (estimated)

Study arms

  • Experimental
    experimental

    Platinum-sensitive recurrent ovarian cancer patients previously treated with a PARP inhibitor, Non-mucinous

    Drug: Niraparib-Bevacizumab

Interventions

  • DrugNiraparib-Bevacizumab

    Niraparib 200mg or 300mg (once daily\[QD\]) Bevacizumab 15mg/kg every 3 weeks (Q3W) \*The recommended starting dosage of niraparib is 200mg QD. For patients who weigh ≥77 kg and have baseline platelet count ≥150,000/μL, the recommended starting dosage is 300 mg QD.

This study also gives NiraparibStudies of NiraparibNiraparib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. progression-free survival(6 months PFS rate)

    To determine the clinical effectiveness of the study treatment assessed using progression free survival(6months) according to RECIST v1.1 criteria (Investigator determined)

    Time frame: 6 months

Secondary outcomes

  1. Overall survival (OS)

    Overall survival (OS) is defined as the time from the first administration of study treatment to death due to any cause. Participants who are alive will be censored at the date of last known contact.

    Time frame: From the first dose of study treatment until death due to any cause, assessed up to 6 years.

  2. Time to tumour progression (TTP)

    Time from the first dose of study treatment to the first documented disease progression according to RECIST version 1.1.

    Time frame: Up to 6 years

  3. Time to First Subsequent Treatment (or Death)

    Time from the first dose of study treatment to the initiation of the first subsequent anticancer therapy or death.

    Time frame: The date of first documented first subsequent treatment or date of death, assessed Up to 6 years

  4. Time to Second Subsequent Treatment (TSST)

    Time from the first dose of study treatment to the initiation of the second subsequent anticancer therapy.

    Time frame: The date of first documented second subsequent treatment assessed up to 6 years

  5. Progression-Free Survival (PFS)

    Time from the first dose of study treatment to the first documented disease progression according to RECIST version 1.1 or death due to any cause, whichever occurs first.

    Time frame: Up to 6 years

  6. Progression-Free Survival 2 (PFS2)

    PFS2 is defined as the time from the first administration of study treatment to the first documented disease progression on the next anticancer therapy or death due to any cause, whichever occurs first.

    Time frame: From the first dose of study treatment until progression on the next anticancer therapy or death, assessed up to 6 years

  7. Incidence of Adverse Events and Serious Adverse Events

    The number and proportion of participants experiencing adverse events (AEs) and serious adverse events (SAEs), graded according to NCI-CTCAE version 5.0.

    Time frame: AEs: Up to 30 days; SAEs: Up to 90 days after the last dose.

07

Study locations

7 sites
08

References and documents

Publications

  • Park J, Lim MC, Lee JK, Jeong DH, Kim SI, Choi MC, Kim BG, Lee JY. A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial. J Gynecol Oncol. 2022 Mar;33(2):e12. doi: 10.3802/jgo.2022.33.e12. Epub 2021 Dec 6. PubMed 34910393 ↗

Individual participant data

Plan to share: No — (Describe the IPD sharing plan, including what IPD are to be shared with other researchers.)

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2021 to primary completion in Jul 2024, 36 months.

Of 229 non-industry phase 2 interventional studies under Ovarian Neoplasms, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 80. This study's 36 months is below that.

Counting every sponsor, half of 345 studies reached it within 47 months; a quarter within 33 and three quarters within 72.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: primary completion Mar 2023 → Jul 2024 and completion Mar 2024 → May 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2021
First posted
Feb 2, 2021
StartActual
Jul 5, 2021
Primary completionActual
Jul 11, 2024was Mar 2023
CompletionEst.
May 31, 2027was Mar 2024
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Active, not recruiting
changed Nov 18, 2026
Sites
6 sites added
Show 6 added (6 South Korea)
  • National Cancer Center · Goyang-si, South Korea
  • CHA Bundang Medical Center · Seongnam-si, South Korea
  • Asan Medical Center · Seoul, South Korea
  • Korea University Guro Hospital · Seoul, South Korea
  • Samsung Medical Center · Seoul, South Korea
  • Seoul National University Hospital · Seoul, South Korea
Nov 18, 2026
Primary completion
Mar 31, 2023→Jul 11, 2024 (actual)
Nov 18, 2026
Study completion
Mar 31, 2024→May 31, 2027
Nov 18, 2026
Eligibility
3 inclusion criteria removed; 33 criteria edited, 21 added
What changed in the criteria
  • Added## Inclusion Criteria
  • AddedParticipants are eligible to be included in the study only if all of the following criteria apply:
  • EditedParticipant has a histologically confirmed diagnosis of high-grade predominantly serous, endometrioid, carcinosarcoma, mixed mullerianMüllerian carcinoma with a high-grade serous component, clear cell, or low-grade serous OCovarian cancer, primary peritoneal cancer, or fallopian tube cancer will be enrolled in this study (only. Only up to 4 patientsparticipants with clear cell carcinoma will be included and mucinous. Mucinous carcinoma will not be included).
  • EditedParticipant has received at least 2 previous courses of platinum-containing therapy, and has disease that was considered platinum -sensitive following the penultimate (next -to -last) platinum course (regimen, defined as more than 12 months' period between penultimate platinum regimen and progression of disease) Note: The last platinum regimen does not necessarily have to immediately follow the next to last (penultimate) platinum regimen. For example, if a patient received a non-platinum regimen between the penultimate platinum regimen and last platinum regimen, they could be eligible, so long as they meet all entry criteriadisease progression.
  • AddedNote: The last platinum regimen does not necessarily have to immediately follow the penultimate platinum regimen. Participants who received a non-platinum regimen between the penultimate and last platinum regimens may be eligible if all other entry criteria are met.
  • EditedParticipant has responded to last the platinum regimenachieved a complete response (completeCR) or partial response (PR) to the last platinum regimen, remains in response, and is enrolled on study within 8 weeks ofafter completion of the last platinum regimen.
  • EditedParticipant hadhas received prior treatment with a PARP inhibitor.
  • EditedParticipant is able to provide a newly obtained core or excisional biopsy of a tumor lesion for prospective testing of BRCA 1BRCA1/2 and PD-L1 status prior to enrollment.
  • EditedFemale participants who are at least participant aged ≥20 years of age on the day of signing informed consent with.
  • EditedParticipant has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, as assessed within 10 days prior to enrollment.
  • EditedA female participant is eligible to participate if sheParticipant is not pregnant (see Appendix 2), notor breastfeeding, and meets at least one of the following conditions applies:
  • EditedNotIs not a woman of childbearing potential (WOCBP), as defined in Appendix 2; OR
  • EditedAIs a WOCBP who agrees to follow the contraceptive guidance in Appendix 2 during the treatment period and for at least 120180 days followingafter the last dose of niraparib and at least 210180 days followingafter the last dose of chemotherapy or bevacizumab.
  • EditedThe participant (orParticipant or a legally acceptable representative if applicable) provides written informed consent for the trial. The participant may also provide consentConsent for future biomedical research; however, the participant may participate is optional and is not required for participation in the main study without participating in future biomedical research.
  • EditedParticipant has adequate organ function as defined inaccording to the following contents; alllaboratory criteria. All screening laboratory tests shouldmust be performed within 10 days prior to the start of study treatment.
  • Added**Hematological Function:**
  • EditedAbsolute neutrophil count (ANC) ≥15001,500/µL.
  • EditedPlateletsPlatelet count ≥100 ,000/µL.
  • EditedHemoglobin ≥9.0 g/dL or ≥5.6 mmol/LaL, without erythropoietin dependency. **Renal Function:**
  • AddedSerum creatinine ≤1.5 × upper limit of normal (ULN); OR
  • AddedMeasured or calculated creatinine clearance (CrCl) ≥30 mL/min for participants with serum creatinine >1.5 × institutional ULN. Glomerular filtration rate (GFR) may be used instead of creatinine or CrCl. CrCl should be calculated according to institutional standards.
  • Added**Hepatic Function:**
  • EditedTotal bilirubin ≤1.5 × ULN; OR direct bilirubin ≤ULN for participants with total bilirubin levels >1.5 × ULN.
  • EditedASTAspartate aminotransferase (SGOTAST) and ALTalanine aminotransferase (SGPTALT) ≤2.5 × ULN (≤5 × ULN for participants with liver metastases).
  • Added**Coagulation Function:**
  • EditedInternational normalized ratio (INR) ORor prothrombin time (PT), Activatedand activated partial thromboplastin time (aPTT) ≤1.5 × ULN, unless the participant is receiving anticoagulant therapy as long as, provided that PT or aPTT is within the therapeutic range offor the intended anticoagulant use of anticoagulants.
  • AddedNote: Laboratory requirements should be adapted according to applicable local regulations and guidelines for the administration of specific chemotherapies.
  • Added## Exclusion Criteria
  • AddedParticipants are excluded from the study if any of the following criteria apply:
  • EditedParticipant has a history of non-infectious pneumonitis that requiredrequiring steroid treatment with steroids or currently has pneumonitis.
  • EditedParticipant either has myelodysplastic syndrome (MDS)/, acute myeloid leukemia (AML), or has features suggestive of MDS/AML.
  • EditedParticipant has a knownan additional malignancy that is progressing or has required active treatment within the past 2 years.
  • AddedExceptions:
  • EditedNote: Participants with basalBasal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g., breast carcinoma, cervical cancercarcinoma in situ, or endometrial carinomacarcinoma) that havehas undergone potentially curative therapy are not excluded.
  • EditedNote: Participants with synchronousSynchronous primary endometrial cancer or a past history of primary endometrial cancer that met the following conditions are not excluded:exceeding Stage not greater than IA:IA, with no more than superficial myometrial invasion.
  • EditedDrainageParticipant has undergone drainage of ascites during the last 2 cycles of lastthe most recent chemotherapy.
  • EditedPalliativeParticipant has received palliative radiotherapy within 1 week encompassing >20% of the bone marrow within 1 week.
  • EditedPersistent > gradeParticipant has persistent toxicity greater than Grade 2 toxicity from prior cancer therapy.
  • EditedSymptomaticParticipant has symptomatic uncontrolled brain or leptomeningeal metastases. A scan to confirmconfirming the absence of brain metastases is not required. PatientsParticipants with spinal cord compression may be consideredeligible if they have received definitive treatment for this and evidence ofhave had clinically stable disease for 28 days.
  • EditedKnownParticipant has known hypersensitivity to the components of niraparib or bevacizumab.

…and 17 more changes, on the record history on ClinicalTrials.gov ↗

Nov 18, 2026
Secondary outcomes
3 edited, 2 time frame changed, 2 added, 2 description edited
What changed in the outcomes
  • EditedTime to first subsequent treatmentFirst Subsequent Treatment (or deathDeath)Time frame: The date of first documented first subsequent treatment or date of death, assessed up to 36months → The date of first documented first subsequent treatment or date of death, assessed Up to 6 years
  • EditedTime to second subsequent treatmentSecond Subsequent Treatment (TSST)Time frame: The date of first documented second subsequent treatment assessed up to 36months → The date of first documented second subsequent treatment assessed up to 6 years
  • EditedprogressionProgression-free survivalFree Survival (PFS)Time frame: Up to 1year → Up to 6 years
  • AddedProgression-Free Survival 2 (PFS2)Time frame: From the first dose of study treatment until progression on the next anticancer therapy or death, assessed up to 6 years
  • AddedIncidence of Adverse Events and Serious Adverse EventsTime frame: AEs: Up to 30 days; SAEs: Up to 90 days after the last dose.
  • Time frameOverall survival (OS)Up to 1year → From the first dose of study treatment until death due to any cause, assessed up to 6 years.
  • Time frameTime to tumour progression (TTP)Up to 1year → Up to 6 years
  • DescriptionOverall survival (OS): how it is measured was reworded
  • DescriptionTime to tumour progression (TTP): how it is measured was reworded
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Status unknown→Active, not recruiting
    6 sites added
    Show 6 added (6 South Korea)
    • National Cancer Center · Goyang-si, South Korea
    • CHA Bundang Medical Center · Seongnam-si, South Korea
    • Asan Medical Center · Seoul, South Korea
    • Korea University Guro Hospital · Seoul, South Korea
    • Samsung Medical Center · Seoul, South Korea
    • Seoul National University Hospital · Seoul, South Korea
    Primary completion Mar 31, 2023→Jul 11, 2024 (now actual)
    Study completion Mar 31, 2024→May 31, 2027
    Eligibility 3 inclusion criteria removed; 33 criteria edited, 21 added
    What changed in the criteria
    • Added## Inclusion Criteria
    • AddedParticipants are eligible to be included in the study only if all of the following criteria apply:
    • EditedParticipant has a histologically confirmed diagnosis of high-grade predominantly serous, endometrioid, carcinosarcoma, mixed mullerianMüllerian carcinoma with a high-grade serous component, clear cell, or low-grade serous OCovarian cancer, primary peritoneal cancer, or fallopian tube cancer will be enrolled in this study (only. Only up to 4 patientsparticipants with clear cell carcinoma will be included and mucinous. Mucinous carcinoma will not be included).
    • EditedParticipant has received at least 2 previous courses of platinum-containing therapy, and has disease that was considered platinum -sensitive following the penultimate (next -to -last) platinum course (regimen, defined as more than 12 months' period between penultimate platinum regimen and progression of disease) Note: The last platinum regimen does not necessarily have to immediately follow the next to last (penultimate) platinum regimen. For example, if a patient received a non-platinum regimen between the penultimate platinum regimen and last platinum regimen, they could be eligible, so long as they meet all entry criteriadisease progression.
    • AddedNote: The last platinum regimen does not necessarily have to immediately follow the penultimate platinum regimen. Participants who received a non-platinum regimen between the penultimate and last platinum regimens may be eligible if all other entry criteria are met.
    • EditedParticipant has responded to last the platinum regimenachieved a complete response (completeCR) or partial response (PR) to the last platinum regimen, remains in response, and is enrolled on study within 8 weeks ofafter completion of the last platinum regimen.
    • EditedParticipant hadhas received prior treatment with a PARP inhibitor.
    • EditedParticipant is able to provide a newly obtained core or excisional biopsy of a tumor lesion for prospective testing of BRCA 1BRCA1/2 and PD-L1 status prior to enrollment.
    • EditedFemale participants who are at least participant aged ≥20 years of age on the day of signing informed consent with.
    • EditedParticipant has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, as assessed within 10 days prior to enrollment.
    • EditedA female participant is eligible to participate if sheParticipant is not pregnant (see Appendix 2), notor breastfeeding, and meets at least one of the following conditions applies:
    • EditedNotIs not a woman of childbearing potential (WOCBP), as defined in Appendix 2; OR
    • EditedAIs a WOCBP who agrees to follow the contraceptive guidance in Appendix 2 during the treatment period and for at least 120180 days followingafter the last dose of niraparib and at least 210180 days followingafter the last dose of chemotherapy or bevacizumab.
    • EditedThe participant (orParticipant or a legally acceptable representative if applicable) provides written informed consent for the trial. The participant may also provide consentConsent for future biomedical research; however, the participant may participate is optional and is not required for participation in the main study without participating in future biomedical research.
    • EditedParticipant has adequate organ function as defined inaccording to the following contents; alllaboratory criteria. All screening laboratory tests shouldmust be performed within 10 days prior to the start of study treatment.
    • Added**Hematological Function:**
    • EditedAbsolute neutrophil count (ANC) ≥15001,500/µL.
    • EditedPlateletsPlatelet count ≥100 ,000/µL.
    • EditedHemoglobin ≥9.0 g/dL or ≥5.6 mmol/LaL, without erythropoietin dependency. **Renal Function:**
    • AddedSerum creatinine ≤1.5 × upper limit of normal (ULN); OR
    • AddedMeasured or calculated creatinine clearance (CrCl) ≥30 mL/min for participants with serum creatinine >1.5 × institutional ULN. Glomerular filtration rate (GFR) may be used instead of creatinine or CrCl. CrCl should be calculated according to institutional standards.
    • Added**Hepatic Function:**
    • EditedTotal bilirubin ≤1.5 × ULN; OR direct bilirubin ≤ULN for participants with total bilirubin levels >1.5 × ULN.
    • EditedASTAspartate aminotransferase (SGOTAST) and ALTalanine aminotransferase (SGPTALT) ≤2.5 × ULN (≤5 × ULN for participants with liver metastases).
    • Added**Coagulation Function:**
    • EditedInternational normalized ratio (INR) ORor prothrombin time (PT), Activatedand activated partial thromboplastin time (aPTT) ≤1.5 × ULN, unless the participant is receiving anticoagulant therapy as long as, provided that PT or aPTT is within the therapeutic range offor the intended anticoagulant use of anticoagulants.
    • AddedNote: Laboratory requirements should be adapted according to applicable local regulations and guidelines for the administration of specific chemotherapies.
    • Added## Exclusion Criteria
    • AddedParticipants are excluded from the study if any of the following criteria apply:
    • EditedParticipant has a history of non-infectious pneumonitis that requiredrequiring steroid treatment with steroids or currently has pneumonitis.
    • EditedParticipant either has myelodysplastic syndrome (MDS)/, acute myeloid leukemia (AML), or has features suggestive of MDS/AML.
    • EditedParticipant has a knownan additional malignancy that is progressing or has required active treatment within the past 2 years.
    • AddedExceptions:
    • EditedNote: Participants with basalBasal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g., breast carcinoma, cervical cancercarcinoma in situ, or endometrial carinomacarcinoma) that havehas undergone potentially curative therapy are not excluded.
    • EditedNote: Participants with synchronousSynchronous primary endometrial cancer or a past history of primary endometrial cancer that met the following conditions are not excluded:exceeding Stage not greater than IA:IA, with no more than superficial myometrial invasion.
    • EditedDrainageParticipant has undergone drainage of ascites during the last 2 cycles of lastthe most recent chemotherapy.
    • EditedPalliativeParticipant has received palliative radiotherapy within 1 week encompassing >20% of the bone marrow within 1 week.
    • EditedPersistent > gradeParticipant has persistent toxicity greater than Grade 2 toxicity from prior cancer therapy.
    • EditedSymptomaticParticipant has symptomatic uncontrolled brain or leptomeningeal metastases. A scan to confirmconfirming the absence of brain metastases is not required. PatientsParticipants with spinal cord compression may be consideredeligible if they have received definitive treatment for this and evidence ofhave had clinically stable disease for 28 days.
    • EditedKnownParticipant has known hypersensitivity to the components of niraparib or bevacizumab.

    …and 17 more changes, on the record history on ClinicalTrials.gov ↗

    Secondary outcomes 3 edited, 2 time frame changed, 2 added, 2 description edited
    What changed in the outcomes
    • EditedTime to first subsequent treatmentFirst Subsequent Treatment (or deathDeath)Time frame: The date of first documented first subsequent treatment or date of death, assessed up to 36months → The date of first documented first subsequent treatment or date of death, assessed Up to 6 years
    • EditedTime to second subsequent treatmentSecond Subsequent Treatment (TSST)Time frame: The date of first documented second subsequent treatment assessed up to 36months → The date of first documented second subsequent treatment assessed up to 6 years
    • EditedprogressionProgression-free survivalFree Survival (PFS)Time frame: Up to 1year → Up to 6 years
    • AddedProgression-Free Survival 2 (PFS2)Time frame: From the first dose of study treatment until progression on the next anticancer therapy or death, assessed up to 6 years
    • AddedIncidence of Adverse Events and Serious Adverse EventsTime frame: AEs: Up to 30 days; SAEs: Up to 90 days after the last dose.
    • Time frameOverall survival (OS)Up to 1year → From the first dose of study treatment until death due to any cause, assessed up to 6 years.
    • Time frameTime to tumour progression (TTP)Up to 1year → Up to 6 years
    • DescriptionOverall survival (OS): how it is measured was reworded
    • DescriptionTime to tumour progression (TTP): how it is measured was reworded
    + 3 other changes: verification date, responsible party and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04734665
Lead sponsor
Yonsei University
Collaborators
Takeda
Responsible party
JUNGYUN LEE (M.D, PhD, Yonsei University) — Principal investigator
First posted
Feb 2, 2021
Start date
Jul 5, 2021
Primary completion
Jul 11, 2024
Completion
May 31, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Jung Yun Lee
principal investigator · Severance Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Niraparib

Start the discussion